RIO DE JANEIRO, Sept. 29, 2016 /PRNewswire-USNewswire/ -- By investing in and leveraging a growing body of clinical researchand economic evidence, Ethicon*, a leader in advancing bariatric and metabolic surgery for more than 20 years, is poised to advance a global conversation on bariatric surgery as a potentially life-saving and health-improving procedure for surgically
Obesity and obesity-related health conditions, including Type 2 Diabetes, are global pandemics. The global price tag runs as high as $2 trillion a year, third only to smoking and armed conflicts. Nearly 30 percent of the world's populations – 2.1 billion people – are either obese or overweight. More than 115 million people in developing countries suffer from obesity-related problems. While Type 2 Diabetes poses a huge economic burden to all nations, developing countries bear the highest burden since more than 80 percent of cases occur in these countries.
"Ethicon's mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems around the world by expanding access to care and demonstrating the critical value of treatment through enabling new technologies, research and evidence." said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation.
Ethicon continues to drive global access to care initiatives to raise awareness of obesity as a chronic disease, and this week at IFSO, Ethicon is showcasing the latest innovations, technologies and new and ongoing clinical and economic evidence.
Ethicon IFSO 2016 highlights:
Advancing the Global Dialogue: At IFSO, Ethicon is leading important conversations on current global, clinical, economic and access to care initiatives to drive a deeper understanding of the issues at hand with the attending bariatric surgeon. Those discussions include:
Supporting Studies around the World on Effectiveness of Bariatric Surgery: Ethicon is investing in a growing body of clinical research and economic evidence to advance a global conversation on bariatric surgery as a potentially life-saving and health-improving procedure for surgically eligible patients suffering from obesity and obesity-related health conditions, particularly diabetes. Studies presented at IFSO include:
Enabling Technology: Ethicon provides best-in-class product solutions for the most demanding bariatric procedures, to help achieve the best surgical outcomes for patients. At IFSO, surgeons will have the opportunity to experience Ethicon's signature products that are designed for the toughest surgical jobs in bariatric surgery.
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world's most pressing health care issues, and improve and save more lives. Through Ethicon's surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com and follow us on Twitter @Ethicon.
Ann Leibson Office: 513-337-8180 [email protected]
* Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ethicon-bolsters-critical-need-for-increased-patient-access-to-most-effective-surgical-treatments-for-obesity-and-metabolic-disease-with-studies-to-be-presented-at-ifso-2016-300336105.html
Subscribe to our Free Newsletters!
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.